Escolar Documentos
Profissional Documentos
Cultura Documentos
Companhia Aberta
CNPJ 60.840.055/0001-31
NIRE 35.300.197.534
FATO RELEVANTE
Nesta mesma data, por meio de sua subsidiária integral, Fleury Centro de
Procedimentos Médicos Avançados S.A., a Companhia também celebrou o
Contrato de Compra e Venda de quotas e Outras Avenças para aquisição de 80%
das quotas de emissão da Clínica de Olhos Dr. Moacir da Cunha Ltda., constituída
por Instituto de Oftalmologia 9 de Julho – Serviços Médicos Ltda., Centro Avançado
de Oftalmologia Ltda. e Clínica de Olhos Dr. Moacir Cunha Ltda. (“Sociedades” ou
“Clínica de Olhos Dr. Moacir Cunha”).
A receita bruta estimada do CIP, nos últimos 12 meses findos em junho de 2020, atingiu
R$ 108,3 milhões.
A receita bruta estimada da Clínica de Olhos Dr. Moacir Cunha, nos últimos 12 meses
findos em março de 2020, atingiu R$ 37,8 milhões.
Material Fact
Fleury SA (“Grupo Fleury” or “Company”), in compliance with paragraph 4 of article 157
of Law 6,404/76 and with CVM´s Instruction 358 of January 3rd, 2002, as amended, informs
to its shareholders and the market in general that, on this date, celebrated the Quota
Purchase and Sale Agreement for the acquisition of 100% of the quotas issued by CIP -
Centro de Infusões Pacaembu LTDA. (“CIP”).
On the same date, through its owned subsidiary, Fleury Centro de Procedimentos Médicos
Avançados S.A, the Company also entered into the Purchase and Sale Agreement for the
quotas and other covenants to acquire 80% of the quotas issued by Clínica de Olhos Dr.
Moacir da Cunha Ltda., constituted by Instituto de Oftalmologia 9 de Julho - Serviços
Médicos Ltda., Centro Avançado de Oftalmologia Ltda. and Clínica de Olhos Dr. Moacir
Cunha Ltda. (“Companies” or “Clínica de Olhos Dr. Moacir Cunha”).
The two acquisitions reinforce the strategy of growth and expansion of the Company's
presence in the healthcare chain with increasingly complete and integrated solutions
through its Platform. These initiatives contribute directly so that people receive
coordinated healthcare, in addition to generating greater sustainability to the system by
optimizing resources.
CIP is a renowned immunobiological infusion center in the State of São Paulo, operating
through 6 patient service centers, all located in the capital.
The estimated gross revenue of CIP, in the last 12 months ended in June 2020, reached R$
108.3 million.
The conclusion of this transaction is subject to certain suspensive conditions, including the
approval of the acquisition by CADE. On the closing date, the Company will pay the
amount of R$ 120.0 million for the acquisition of CIP.
of the Appraisal Report will be released to the market in due course, and the Company
should inform, at the time, whether or not the acquisition should be subject to ratification
at a general shareholders' meeting.
The Clínica de Olhos Dr. Moacir Cunha is one of the most traditional ophthalmology
centers in the State of São Paulo, currently in the fourth generation of ophthalmologists,
with 80 years of history marked by medical excellence and quality service.
The estimated gross revenue of Clínica de Olhos Dr. Moacir Cunha, in the last 12 months
ended in March 2020, reached R$ 37.8 million.
The acquisition of the Clínica de Olhos Dr. Moacir Cunha will take place, on the closing
date, of the three companies that constitute it and that operate in ophthalmological
medical services in the one stop shop model, performing consultations, tests and surgeries
in two patient service centers in the city of São Paulo.
The conclusion of this transaction is subject to certain precedent conditions. On the closing
date, the Company will pay the amount of R$ 29.5 million for the acquisition of Clínica de
Olhos Dr. Moacir Cunha.
This acquisition is not subject to the Company's shareholders' decision, nor will it give rise to
the right to withdraw, in view of the terms of item 7.3 of Official Letter CVM/SEP/No.
02/2020.
The Company will keep its shareholders and the market informed about the facts related
to both transactions.